CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 2 enrolled
Drug / intervention
erlotinib hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01592383
NCT01592383Phase 2Completed
CompareCT.gov

Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations

University of Chicago·interventional·Posted May 7, 2012·Updated Oct 16, 2018

In Brief

A Phase 2 clinical trial evaluating erlotinib hydrochloride for Malignant Peritoneal Mesothelioma. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer. Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other cancers, but erlotinib has not been approved for malignant peritoneal mesothelioma. This research is being done because there is no current standard treatment for malignant peritoneal mesothelioma and the study doctors want to see how erlotinib affects malignant peritoneal mesothelioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Peritoneal Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2012
Enrollment StartJun 1, 2012
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.2 years ago

Interventions

erlotinib hydrochloridedrug

Given PO